{"filing":{"accession_number":"0001104659-26-104368","cik":"0001828185","ticker":"BRNS","company_name":"Barinthus Biotherapeutics plc.","form":"8-K","filing_date":"2026-09-01","report_date":"2026-09-01","primary_document":"tm2624619d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926104368/tm2624619d1_8k.htm"},"events":[{"id":31074,"run_id":28496,"accession_number":"0001104659-26-104368","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Barinthus Biotherapeutics plc's Scheme of Arrangement with Clywedog Therapeutics, Inc. was sanctioned by the High Court on September 1, 2026, and is expected to become effective on September 9, 2026, resulting in a change of control and delisting of the company's ADSs from Nasdaq.","company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","filing_date":"2026-09-01","form":"8-K","submitted_at":null,"items":[{"id":33867,"accession_number":"0001104659-26-104368","item_number":"3.01","item_title":"Notice of Delisting or Failure","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Item 3.01 explicitly addresses \"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.\" The filing references Item 8.01 for substantive details, indicating the registrant has disclosed a delisting notice or listing compliance failure. This is a terminal event materially affecting the registrant's continued public trading status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T21:14:42.382866+00:00","company_name":"","ticker":null,"filing_date":""},{"id":33868,"accession_number":"0001104659-26-104368","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a material acquisition transaction: the Scheme of Arrangement between Barinthus Biotherapeutics plc and Clywedog Therapeutics, Inc. (via merger subsidiaries) was sanctioned by the High Court on September 1, 2026, and is expected to become effective on September 9, 2026. This represents completion of a material M\u0026A transaction that will result in a change of control and delisting of the company's ADSs from Nasdaq, directly affecting investor interests.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T21:14:42.382866+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33867,"accession_number":"0001104659-26-104368","item_number":"3.01","item_title":"Notice of Delisting or Failure","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Item 3.01 explicitly addresses \"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.\" The filing references Item 8.01 for substantive details, indicating the registrant has disclosed a delisting notice or listing compliance failure. This is a terminal event materially affecting the registrant's continued public trading status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T21:14:42.382866+00:00","company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","filing_date":"2026-09-01"},{"id":33868,"accession_number":"0001104659-26-104368","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a material acquisition transaction: the Scheme of Arrangement between Barinthus Biotherapeutics plc and Clywedog Therapeutics, Inc. (via merger subsidiaries) was sanctioned by the High Court on September 1, 2026, and is expected to become effective on September 9, 2026. This represents completion of a material M\u0026A transaction that will result in a change of control and delisting of the company's ADSs from Nasdaq, directly affecting investor interests.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T21:14:42.382866+00:00","company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","filing_date":"2026-09-01"}]}